https://biotechmorning.com/news/teva-weltruza-schizophrenia-monthly-injection-fda-approval Biotech Morning en 2026-10-18T14:17:59.021Z The Schizophrenia Shot That Ditches the Biggest Safety Headache https://biotechmorning.com/news/roche-billion-dollar-dualitas-bispecific-screening-deal Biotech Morning en 2026-10-18T14:17:07.996Z Roche Is Betting $1 Billion on a Startup That Barely Exists https://biotechmorning.com/news/verastem-kras-g12d-pancreatic-cancer-data Biotech Morning en 2026-10-18T14:16:20.593Z The Cancer Target Nobody Could Hit for 40 Years Just Got Hit Again https://biotechmorning.com/news/undruggable-kras-conquers-europe-pancreatic-cancer Biotech Morning en 2026-10-18T14:15:30.957Z The 'Undruggable' Cancer Target That Just Conquered Europe https://biotechmorning.com/news/intellia-crispr-phase-3-hereditary-angioedema Biotech Morning en 2026-10-18T14:14:45.731Z One Shot to Silence a Disease Forever https://biotechmorning.com/news/astrazeneca-absci-ai-antibody-deal Biotech Morning en 2026-10-18T14:13:58.883Z AstraZeneca Is Letting AI Design Its Next Cancer Drug From Scratch https://biotechmorning.com/news/biontech-mRNA-cancer-vaccine-bnt113-fails-phase-3 Biotech Morning en 2026-10-18T14:13:13.006Z BioNTech Bet Big on mRNA Beating Cancer. The Cancer Won. https://biotechmorning.com/news/once-weekly-achondroplasia-therapy-europe Biotech Morning en 2026-10-18T14:12:28.383Z One Shot a Week Could Change Everything for Kids With Achondroplasia https://biotechmorning.com/news/novartis-fabhalta-lupus-nephritis-trial-halted Biotech Morning en 2026-10-18T14:11:44.020Z Novartis Just Pulled the Plug on Fabhalta's Biggest Ambition https://biotechmorning.com/news/bms-orbital-therapeutics-1-5-billion-acquisition Biotech Morning en 2026-10-18T14:10:55.404Z BMS Just Paid $1.5 Billion for a Company With Zero Approved Drugs https://biotechmorning.com/news/adc-that-couldnt-clear-the-bar Biotech Morning en 2026-10-18T14:10:12.303Z The ADC That Couldn't Clear the Bar https://biotechmorning.com/news/novartis-kills-fabhalta-kidney-trial-strategic-reasons Biotech Morning en 2026-10-17T14:14:57.801Z Novartis Just Killed a Trial of Its Own Blockbuster Drug. Nobody Knows Why. https://biotechmorning.com/news/fda-approves-enspryng-thyroid-eye-disease-mixed-data Biotech Morning en 2026-10-17T14:14:11.282Z The FDA Just Approved a Drug That Failed One of Its Own Tests https://biotechmorning.com/news/caribou-biosciences-shutdown-crispr-doudna Biotech Morning en 2026-10-17T14:13:24.112Z A Nobel Laureate's Biotech Just Ran Out of Road https://biotechmorning.com/news/astrazeneca-2-billion-summit-therapeutics-cancer-deal Biotech Morning en 2026-10-17T14:12:41.086Z AstraZeneca Just Wrote a $2 Billion Check to a Company Most People Haven't Heard Of https://biotechmorning.com/news/estuary-biotherapeutics-adpkd-gene-therapy-launch Biotech Morning en 2026-10-17T14:11:54.032Z $103M to Fix the Gene That's Slowly Destroying 1 in 1,000 Kidneys https://biotechmorning.com/news/biotech-ipo-drought-over-2026 Biotech Morning en 2026-10-17T14:11:06.404Z Biotech's IPO Drought Is Officially Over. What Broke the Spell? https://biotechmorning.com/news/novo-nordisk-orbis-medicines-oral-cardiometabolic-deal Biotech Morning en 2026-10-17T14:10:19.788Z Novo Nordisk's $1.4 Billion Bet That Pills Can Replace Needles https://biotechmorning.com/news/hhs-ai-clinical-trials-initiative Biotech Morning en 2026-10-17T14:09:33.969Z Uncle Sam Wants AI to Run Your Clinical Trials